Recent advancements in Alzheimer's disease (AD) treatment, particularly with disease-modifying therapies (DMTs) like lecanemab and donanemab, have sparked hope for millions. However, a new study from Trinity College, published in Alzheimer's & Dementia, reveals a stark reality: at current market prices, these therapies are financially inaccessible across 174 countries, exacerbating global health inequities. This analysis goes beyond the original coverage by examining the systemic issues of healthcare access, the historical context of drug pricing disparities, and the broader implications for chronic disease management worldwide.

The Trinity College study, an observational analysis with a simulation model, underscores that neither lecanemab nor donanemab is cost-effective at current prices, with US market prices exceeding value-based estimates by 182% and 129%, respectively. This pricing gap is particularly devastating for low- and middle-income countries (LMICs), where even significant clinical benefits cannot justify costs without drastic price reductions. What the original coverage missed is the deeper structural issue: the pharmaceutical industry's pricing models often prioritize high-income markets, sidelining LMICs despite their disproportionate burden of aging populations. For instance, the World Health Organization (WHO) estimates that by 2050, 68% of people with dementia will live in LMICs, yet these regions are least equipped to absorb high-cost treatments.

This issue is not isolated to AD. Historical patterns, such as the delayed access to HIV/AIDS treatments in sub-Saharan Africa during the 1990s and early 2000s due to pricing barriers, mirror the current crisis. Then, as now, international advocacy and generic drug agreements eventually lowered costs, but only after millions suffered from delayed access. The original coverage also overlooked the potential role of public-private partnerships or tiered pricing models, which have shown promise in other disease areas like malaria and tuberculosis, as seen in initiatives by the Global Fund. Without such interventions, the AD treatment gap risks becoming a decades-long equity failure.

Moreover, the study’s focus on country-specific value-based pricing highlights a critical oversight in global health policy: the lack of standardized frameworks for assessing drug affordability across diverse economic contexts. While the researchers provide a starting point, they do not address the political and logistical challenges of implementing differential pricing, such as resistance from pharmaceutical companies citing R&D costs. A 2021 study in The Lancet Global Health noted that while tiered pricing can work, it often requires binding international agreements—something absent in the AD space.

The implications extend beyond AD patients to health systems at large. High-cost DMTs strain budgets, potentially diverting resources from other critical areas like primary care or preventive health in LMICs. This mirrors trends seen with cancer therapies, where high costs have led to rationing in even high-income settings, as documented in a 2019 JAMA Oncology report. Without addressing these systemic issues, the promise of AD breakthroughs risks becoming a privilege for the few rather than a right for the many.

In conclusion, while lecanemab and donanemab represent scientific progress, their real-world impact hinges on dismantling financial barriers. This requires not just price reductions but also innovative policy solutions, global cooperation, and a reckoning with the inequities baked into healthcare access. The Trinity study is a wake-up call—one that demands action before another generation of AD patients is left behind.